| Literature DB >> 21197340 |
Dharshan Anandacoomaraswamy1, Jagdeesh Ullal, Aaron I Vinik.
Abstract
This is a case of a 70-year-old man with severe peripheral neuropathy, type 2 diabetes and progressively worsening cerebellar ataxia. He was found to have circulating antigliadin and antireticulin antibodies compatible with celiac disease in the absence of intestinal pathology. The peripheral neuropathy improved with a gluten-free diet, antioxidants and intravenous immunoglobulin, whereas the ataxia did not. This case illustrates the need to test for celiac disease in patients with idiopathic ataxia and peripheral neuropathy and the need for alternative therapies for ataxia.Entities:
Keywords: autoimmune disease; celiac disease; cerebellar ataxia; peripheral neuropathy; type 2 diabetes
Year: 2008 PMID: 21197340 PMCID: PMC3004541 DOI: 10.2147/jmdh.s3018
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Quantitative measures of peripheral sensory threshold indices and autonomic function done at the time of presentation and after 17 months of treatment. Measures of peripheral neuropathy are vibration and pressure sensations, warm and cold perceptions and painful perception (Vinik et al 1995). The E/I (exipiratory/inspiratory ratio), 30:15 stand test and valsalva are measures of autonomic nerve function (Vinik and Erbas 2001)
| Neuropathy t tests(units) | At presentation | After 17 months | Normal values for >90% specificity |
|---|---|---|---|
| Vibration (volts) | 9.11 | 3.63 | 0–6.1 |
| Pressure (log g) | 4.13 | 3.58 | 0–3.95 |
| Cold perception (°C) | 8.6 | 9.2 | 0–10.5 |
| Warm Perception (°C) | 10.3 | 9.3 | 0–12.4 |
| Cold pain(°C) | 24 | 11.1 | 0–23.3 |
| Warm pain (°C) | 15.5 | 10.4 | 0–17.7 |
| E/I | 1.11 | 1.06 | >1.08 |
| Valsalva | 1.57 | 1.21 | >1.15 |
| 30:15 ratio | 1.13 | 1.05 | >1.08 |
Figure 1This figure represents the progressive changes in central and peripheral nervous system scores. The central nervous system (CNS) signs score is the sum of the number of positive cerebellar signs. The total peripheral neuropathy impairment scores and sensory scores were obtained from our clinical evaluation scoring system (Vinik et al 2005b) modified from the Rochester Diabetic Neuropathy Study (Dyck et al 1992). In this system a score of 1 or 0 is given for the presence or absence of neuropathy symptom respectively. Motor, sensory and autonomic nervous systems are evaluated and given scores on a scale of 0 to 4, 0 being no impairment and 4 being severe impairment. Antioxidant treatment instituted at point A, IV Ig infusion instituted at point B and Point C is when gluten free diet was started.